10493 INTEGRASEVPA - MK-0518 INTENSIFICATION AND HDAC INHIBITION IN DEPLETION OF

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Purpose: This study will test the hypotheses that the frequency of HIV infection within resting CD4+ T cells will be progressively decreased over time by the combination of valproate and intensified ART. Participants: HIV-1 infection men and women age =18 years on potent antiretroviral therapy, defined as at least 2 NRTIs plus at least 1 PI or NNRTI, without changes in the 24 weeks immediately prior to entry. Procedures (methods): This is an open-label pilot study of 24 weeks to 48 weeks of study treatment. Participants must meet all of the study inclusion and exclusion criteria in order to participate in this study. Subjects will continue current ART for the duration of the study. There are 2 steps: Step 1: Subjects will continue current ART and add MK-0518 at 400 mg po BID. Step 2: VPA is discontinued in all patients upon entry into Step 2, after leukopheresis at week 24.